Global Pre-menstrual Syndrome Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025

  • ID: 4431787
  • Report
  • Region: Global
  • Acute Market Reports
1 of 4

FEATURED COMPANIES

  • Bayer, Inc.
  • Chattem, Inc. (Sanofi)
  • DEKK-TEC, Inc.
  • MetP Pharma AG
  • Novart
  • Umecrine Mood AB
  • MORE
Pre-menstrual Syndrome Treatment Market - Growth, Future Prospects, and Competitive Analysis, 2017 - 2025, the global pre-menstrual syndrome treatment market was valued at US$ 43,30.2 Mn in 2017, and is expected to reach US$ 59,82.8 Mn by 2025, expanding at a CAGR of 2.0% from 2017 to 2025.

Market Insights

Pre-menstrual syndrome (PMS) is defined as a condition that affects women at childbearing age and is characterized by symptoms such as bloating, pain, breast tenderness, body pain, fatigue, mood fluctuation, anxiety, etc. where the exact cause of PMS is unknown. According to the American Psychiatric Association, U.S. almost 90% of women of child bearing age experience premenstrual symptoms and less than 10% are diagnosed with premenstrual dysphoric disorder (PMDD). PMDD is a severe and disabling form of PMS affecting 3-8% of women. Some of the therapies used for treatment of pre-menstrual syndrome are changes in diet, home remedies, medications, psychological therapy, supplements and others. Government and non-government agencies’ campaigns towards elevating the status of female health and education has attributed to significant growth in demand for female hygiene products and also PMS treatment drugs. Further growth in female education and the number of working female population will contribute to the demand for PMS drugs in the region.

The global pre-menstrual syndrome treatment market is segmented by drug type as analgesics (pain killers), oral contraceptive pills (OCPs), gonadotropin-releasing hormone (GnRH), antidepressants, ovarian suppressors, diuretics and benzodiazepines. Common painkillers available for treating PMS are NSAIDS and paracetamol. This segment is majorly dominated by over-the-counter drugs that are cheap and easily available in the market

As of the current market scenario, North America and Europe together dominate the pre-menstrual syndrome treatment market due to increase in prevalence of pre-menstrual syndrome and higher awareness about PMS and prevailing treatment options. Asia Pacific, and Middle East and Africa together present lucrative opportunities to manufacturers offering PMS treatment drugs. Large pool of females in childbearing age, growing literacy rate and working population significantly contribute to growing opportunities in the region. Growing number of government initiatives and campaigns focusing on women and maternity health are further driving the market growth.

Market Competition Assessment

Key players in the global pre-menstrual syndrome treatment market are
Alva-Amco Pharmacal Cos., Inc., Bayer, Inc., Chattem, Inc. (Sanofi), DEKK-TEC, Inc., G. R. Lane Health Products Ltd., McNeil Consumer Healthcare, MetP Pharma AG, Pherin Pharmaceuticals, Inc., Umecrine Mood AB, Novartis AG, GlaxoSmithKline Plc and others.

Key Market Movements:
  • Increasing awareness among young women about premenstrual syndrome especially in developed economies is one of the driving factor for the growth of the PMS treatment market
  • Rising awareness due to several government and non-government campaigns is expected to boost the sale of the medical drugs used to treat PMS
  • Easy availability of OTC PMS treatment drugs, the access to treatments have become easier, thus further supporting the market growth
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bayer, Inc.
  • Chattem, Inc. (Sanofi)
  • DEKK-TEC, Inc.
  • MetP Pharma AG
  • Novart
  • Umecrine Mood AB
  • MORE
Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I - Secondary Research
1.3.2 Phase II - Primary Research
1.3.3 Phase III - Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Pre-menstrual Syndrome Treatment Market Portraiture
2.2 Global Pre-menstrual Syndrome Treatment Market Share, by Drug type, 2015 (US$ Mn)
2.3 Global Pre-menstrual Syndrome Treatment Market, by Geography, 2015 (Value %)

Chapter 3 Global Pre-menstrual Syndrome Treatment Market Analysis
3.1 Global Pre-menstrual Syndrome Treatment Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.1.1 Growing Awareness about PMS has Attracted the Demand for PMS Management Drugs
3.2.2 Challenges
3.2.2.1 Lack of Social Appreciation and Attachment of Stigma
3.2.3 Opportunities
3.2.3.1 Proliferation of Basic Healthcare Campaigns and Initiatives
3.3 Attractive Investment Proposition
3.4 Competitive Landscape of Key Players in Pre-menstrual Syndrome Treatment Market

Chapter 4 Global Pre-menstrual Syndrome Treatment Market Analysis, by Drugs Type, 2015 - 2025 (US$ Mn)
4.1 Introduction
4.2 Analgesics (pain killers)
4.3 Oral Contraceptive Pills (OCPs)
4.4 Gonadotropin-releasing Hormone (GnRH)
4.5 Antidepressants
4.6 Ovarian Suppressors
4.7 Diuretics
4.8 Benzodiazepines

Chapter 5 Global Pre-menstrual Syndrome Treatment Market, By Geography, 2015 - 2025 (US$ Mn)
5.1 Preface
5.2 North America (U.S. & Canada)
5.3 Europe (U.K., Germany & Rest of Europe)
5.4 Asia Pacific (China, Japan, and Rest of APAC)
5.5 Latin America
5.6 Middle East and Africa (UAE, Saudi Arabia, South Africa)

Chapter 6 Company Profiles
6.1 Alva-Amco Pharmacal Cos., Inc.
6.2 Bayer, Inc.
6.3 Chattem, Inc. (Sanofi)
6.4 DEKK-TEC, Inc.
6.5 G. R. Lane Health Products Ltd
6.6 McNeil Consumer Healthcare
6.7 MetP Pharma AG
6.8 Pherin Pharmaceuticals, Inc.
6.9 Umecrine Mood AB
6.10 Umecrine Mood AB
6.11 Novartis AG
6.12 GlaxoSmithKline Plc

List of Figures
Fig. 1 Global Pre-menstrual Syndrome Treatment Market: Research Methodology
Fig. 2 Global Pre-menstrual Syndrome Treatment Market Share, by Drug type, 2015 (US$ Mn)
Fig. 3 Global Pre-menstrual Syndrome Treatment Market, by Geography, 2015 (Value %)
Fig. 4 Attractive Investment Proposition: Global Pre-menstrual Syndrome Treatment Market, by Geography
Fig. 5 Competitive Analysis: Key Players in Global Pre-menstrual Syndrome Treatment Market
Fig. 6 Pre-menstrual Syndrome Treatment Analgesics (pain killers) Market, 2015 - 2025 (US$ Mn)
Fig. 7 Pre-menstrual Syndrome Treatment Oral Contraceptive Pills (OCPs) Market, 2015 - 2025 (US$ Mn)
Fig. 8 Pre-menstrual Syndrome Treatment Gonadotropin-releasing Hormone (GnRH) Market, 2015 - 2025 (US$ Mn)
Fig. 9 Pre-menstrual Syndrome Treatment Antidepressants Market, 2015 - 2025 (US$ Mn)
Fig. 10 Pre-menstrual Syndrome Treatment Ovarian Suppressors Market, 2015 - 2025 (US$ Mn)
Fig. 11 Pre-menstrual Syndrome Treatment Diuretics Market, 2015 - 2025 (US$ Mn)
Fig. 12 Pre-menstrual Syndrome Treatment Benzodiazepines Market, 2015 - 2025 (US$ Mn)

List of Tables
Table 1 Global Pre-menstrual Syndrome Treatment Market, 2014-2024 (US$ Mn)
Table 2 Global Pre-menstrual Syndrome Treatment Market, by Geography, 2015 - 2025 (US$ Mn)
Table 3 North America Pre-menstrual Syndrome Treatment Market, by Country, 2015 - 2025 (US$ Mn)
Table 4 Europe Pre-menstrual Syndrome Treatment Market, by Country, 2015 - 2025 (US$ Mn)
Table 5 Asia-Pacific Pre-menstrual Syndrome Treatment Market, by Country, 2015 - 2025 (US$ Mn)
Table 6 Latin America Pre-menstrual Syndrome Treatment Market, by Country, 2015 - 2025 (US$ Mn)
Table 7 Middle East and Africa Pre-menstrual Syndrome Treatment Market, by Country, 2015 - 2025 (US$ Mn)
Table 8 Alva-Amco Pharmacal Cos., Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 9 Bayer, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 10 Chattem, Inc. (Sanofi): Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 11 DEKK-TEC, Inc.: Company Snapshot (Business Description; Financial Performance; Product Position Portfolio; News Coverage)
Table 12 G. R. Lane Health Products Ltd: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 13 McNeil Consumer Healthcare: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 14 MetP Pharma AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
Table 15 Pherin Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 16 Umecrine Mood AB: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 17 Umecrine Mood AB: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 18 Novartis AG: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Table 19 GlaxoSmithKline Plc: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Alva-Amco Pharmacal Cos., Inc.
  • Bayer, Inc.
  • Chattem, Inc. (Sanofi)
  • DEKK-TEC, Inc.
  • G. R. Lane Health Products Ltd
  • McNeil Consumer Healthcare
  • MetP Pharma AG
  • Pherin Pharmaceuticals, Inc.
  • Umecrine Mood AB
  • Umecrine Mood AB
  • Novart
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll